Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome.

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arbaclofen (Primary)
  • Indications Social isolation
  • Focus Registrational; Therapeutic Use
  • Acronyms Harbor-C

    • Most Recent Events

    • 14 Jul 2022 According to an Allos Pharma media release, results from this trial will be presented at the 18th NFXF International Fragile X Conference 2022.
    • 14 Jul 2022 Results published in an Allos Pharma Media Release.
    • 14 Jul 2022 Primary endpoint Aberrant Behavior Checklist (Change in the Lethargey Social Withdrawal subscale.) has been met, according to an Allos Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top